> Detailanzeige

Kim, Min Jung; Kang, Hyo‐Gyoung; Lee, Shin Yup; Jeon, Hyo‐Sung; Lee, Won‐Kee; Park, Ji Young; Lee, Eung Bae; Lee, Jae Hee; Cha, Sung‐Ick; Kim, Dong Sun; Kim, Chang‐Ho; Kam, Sin; Jung, Tae Hoon; Park, Jae Yong

AKT1 polymorphisms and survival of early stage non‐small cell lung cancer

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: AKT1 polymorphisms and survival of early stage non‐small cell lung cancer
  • Beteiligte: Kim, Min Jung; Kang, Hyo‐Gyoung; Lee, Shin Yup; Jeon, Hyo‐Sung; Lee, Won‐Kee; Park, Ji Young; Lee, Eung Bae; Lee, Jae Hee; Cha, Sung‐Ick; Kim, Dong Sun; Kim, Chang‐Ho; Kam, Sin; Jung, Tae Hoon; Park, Jae Yong
  • Erschienen: Wiley, 2012
  • Erschienen in: Journal of Surgical Oncology
  • Sprache: Englisch
  • DOI: 10.1002/jso.22071
  • ISSN: 0022-4790; 1096-9098
  • Schlagwörter: Oncology ; General Medicine ; Surgery
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background and Objectives:</jats:title><jats:p>This study was conducted to investigate the impact of polymorphisms in the <jats:italic>AKT</jats:italic>1 gene on the survival of early stage non‐small cell lung cancer (NSCLC) patients.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>Three hundred and ten patients with surgically resected NSCLC were enrolled. The rs3803300, rs1130214, rs3730358, rs1130233, and rs2494732 single nucleotide polymorphisms (SNPs) in the <jats:italic>AKT</jats:italic>1 gene were investigated. The genotype and haplotype associations with overall survival (OS) and disease free survival (DFS) were analyzed.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>The three SNPs (rs3803300, rs1130214, and rs2494732) were significantly associated with survival outcomes on multivariate analysis. When the three SNPs were combined, OS and DFS were decreased in a dose‐dependent manner as the number of bad genotypes increased (<jats:italic>P</jats:italic><jats:sub>trend</jats:sub> = &lt;1.0 × 10<jats:sup>−4</jats:sup> and 0.001, respectively). Patients with 2 bad genotypes had a significantly worse OS and DFS compared with those with 0 bad genotypes (adjusted hazard ratio (HR) = 3.08, 95% confidence interval (CI) = 1.61–5.89, <jats:italic>P</jats:italic> = 0.001; and adjusted HR = 2.04, 95% CI = 1.22–3.43, <jats:italic>P</jats:italic> = 0.01).</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>These results suggest that the <jats:italic>AKT</jats:italic>1 polymorphisms could be used as prognostic markers for the patients with early‐stage NSCLC. J. Surg. Oncol. 2012; 105:167–174. © 2011 Wiley Periodicals, Inc.</jats:p></jats:sec>